Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motavizumab for RSV Prevention in Native American Infants
NCT00121108Phase 3Completed
- Sponsor
- MedImmune
- Start
- Nov 2004
- Primary completion
- Dec 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing Motavizumab Arm with Placebo Arm (2 arms). Primary endpoint: Number of Participants With Respiratory Syncytial Virus (RSV) Hospitalization at Day 150. Started Nov 2004; status: completed.
02
Drugs
motavizumab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT00121108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121108.